Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Molecular Diagnostics

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jmoldx.2017.11.004PMID 29398453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

  2017cited by this paper
• Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

  2017cited by this paper
• ERBB2‐Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

  2017cited by this paper
• Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

  2017cited by this paper
• Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

  2017cited by this paper
• ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellsch

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

  2017cited by this paper
• Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

  2017cited by this paper
• Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

  2017cited by this paper
• High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1‐Positive Metastatic Lung Cancer

  2017cited by this paper
• Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

  2017cited by this paper
• Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  2017cited by this paper
• Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

  2016cited by this paper
• ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

  2016cited by this paper
• The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology.

  2016cited by this paper
• Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

  2016cited by this paper
• Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

  2016cited by this paper
• MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

  2016cited by this paper
• Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease

  2016cited by this paper
• Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

  2016cited by this paper
• Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

  2016cited by this paper
• Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

  2016cited by this paper
• Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

  2016cited by this paper
• Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

  2016cited by this paper
• ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

  2016cited by this paper
• MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

  2016cited by this paper
• Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis

  2016cited by this paper
• A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

  2016cited by this paper
• Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology

  2016cited by this paper
• Reliability Assurance of Detection of EML4‐ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China

  2016cited by this paper
• EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

  2016cited by this paper
• Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

  2016cited by this paper
• Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

  2016cited by this paper
• Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

  2015cited by this paper
• Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

  2015cited by this paper
• EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

  2015cited by this paper
• Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

  2015cited by this paper
• Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

  2015cited by this paper
• Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

  2015cited by this paper
• Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

  2015cited by this paper
• Epidermal Growth Factor Receptor–Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options

  2015cited by this paper
• Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

  2015cited by this paper
• Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

  2015cited by this paper
• MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.

  2015cited by this paper
• Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

  2015cited by this paper
• Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma

  2015cited by this paper
• Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

  2015cited by this paper
• Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.

  2015cited by this paper
• SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

  2015cited by this paper
• Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  2015cited by this paper
• A Novel, Highly Sensitive ALK Antibody 1A4 Facilitates Effective Screening for ALK Rearrangements in Lung Adenocarcinomas by Standard Immunohistochemistry

  2015cited by this paper
• Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

  2015cited by this paper
• Clinical Implications of Variant ALK FISH Rearrangement Patterns

  2015cited by this paper
• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

  2015cited by this paper
• Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

  2015cited by this paper
• ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

  2015cited by this paper
• Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

  2015cited by this paper
• Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

  2015cited by this paper
• Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor

  2015cited by this paper
• Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.

  2015cited by this paper
• Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma

  2015cited by this paper
• HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.

  2015cited by this paper
• Validation of new cancer biomarkers: a position statement from the European group on tumor markers.

  2015cited by this paper
• The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability

  2015cited by this paper
• Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR

  2015cited by this paper
• Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

  2015cited by this paper
• French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas

  2015cited by this paper
• Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cance

  2014cited by this paper
• Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

  2014cited by this paper
• Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies.

  2014cited by this paper
• Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

  2014cited by this paper
• Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry

  2014cited by this paper
• Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH

  2014cited by this paper
• Prognostic and predictive biomarkers in lung cancer. A review

  2014cited by this paper
• Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay

  2014cited by this paper
• Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

  2014cited by this paper
• Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR

  2014cited by this paper
• MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas

  2014cited by this paper
• Gefitinib Treatment in EGFR Mutated Caucasian NSCLC

  2014cited by this paper
• Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements

  2014cited by this paper
• Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group

  2014cited by this paper
• Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer

  2014cited by this paper
• Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

  2014cited by this paper
• Anchored multiplex PCR for targeted next-generation sequencing

  2014cited by this paper
• On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

  2014cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014cited by this paper
• HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.

  2014cited by this paper

• The fundamental role of liquid biopsy in lung cancer: a shift in paradigm in the realm of thoracic oncology

  2026cites this paper
• Actionable driver gene alterations in early-stage non-small cell lung cancer: a review

  2026cites this paper
• Multimodal ultrasonography for predicting epidermal growth factor receptor mutation in subpleural non-small cell lung carcinoma

  2026cites this paper
• Reporte de caso: ALKOMA oculto o emergente en una paciente no fumadora con cáncer de pulmón de célula no pequeña metastásico

  2026cites this paper
• Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study

  2026cites this paper
• Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia

  2025cites this paper
• Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study

  2025cites this paper
• Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time

  2025cites this paper
• Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications

  2025cites this paper
• Genomics and the early diagnosis of lung cancer.

  2025cites this paper
• Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies

  2025cites this paper
• Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management

  2025cites this paper
• General practitioners’ attitudes towards liquid biopsy as a diagnostic test for advanced lung cancer

  2025cites this paper
• 1H NMR Relaxation Processes in Lung Tissues at Low Magnetic Fields

  2025cites this paper
• Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study

  2025cites this paper
• Pulmonary cytology: Pearls and pitfalls of non‐neoplastic mimics of lung cancer

  2025cites this paper
• Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study.

  2025cites this paper
• EGFR mutation testing across the osimertinib clinical program.

  2025cites this paper
• Artificial intelligence-based pharmacological approach in non-small cell lung cancer in the precision medicine era.

  2025cites this paper
• Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non–Small Cell Lung Cancer in the United States

  2025cites this paper
• Large Cell Neuroendocrine Carcinoma of the Lung: In Search for a Better Definition.

  2025cites this paper
• Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer.

  2025cites this paper
• Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis

  2025cites this paper
• Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives.

  2025cites this paper
• Multimodal radiomic analysis to determine high-Consistency prognostic phenotypes associated with epidermal growth factor receptor mutations in non-small cell lung cancer brain metastases.

  2025cites this paper
• Challenges and Strategic Responses to Head and Neck Cancer Care in Nigeria, West African Subregion: A Narrative Review

  2025cites this paper
• Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project

  2025cites this paper
• Prevailing challenges in companion diagnostic test development for lung cancer

  2025cites this paper
• Developing Consensus for a More Provider-Friendly Next Generation Sequencing Molecular Biomarker Report: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  2025cites this paper
• Ultra-Rapid EGFR Testing in Non-Small Cell Lung Carcinoma Patients: Findings from a Canadian Clinical Testing Workflow.

  2025cites this paper
• Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy

  2025cites this paper
• Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology

  2025cites this paper
• BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practice

  2025cites this paper
• Isoorientin: Unveiling the hidden flavonoid's promise in combating cancer development and progression - A comprehensive review.

  2024cites this paper
• Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study

  2024cites this paper
• A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens

  2024cites this paper
• Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)

  2024cites this paper
• lncRNAs’p potential roles in the pathogenesis of cancer via interacting with signaling pathways; special focus on lncRNA-mediated signaling dysregulation in lung cancer

  2024cites this paper
• Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer.

  2024cites this paper
• The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study

  2024cites this paper
• Молекулярні біомаркери в менеджменті пацієнтів з недрібноклітинним раком легень

  2024cites this paper
• An explorative analysis on the optimal cryo-passes and freezing time of the ultrathin cryoprobe in endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy

  2024cites this paper
• Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

  2024cites this paper
• Molecular Methods: Clinical Utilization and Designing a Test Menu.

  2024cites this paper
• Preclinical Models for Functional Precision Lung Cancer Research

  2024cites this paper
• Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation

  2024cites this paper
• Benefits of Implementing Reflex Genomic Analysis for Nonsmall Cell Lung Cancer.

  2024cites this paper
• Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer

  2024cites this paper
• The World Health Organization Reporting System for Lung Cytopathology–A Review of the First Edition

  2024cites this paper
• Precision Medicine in Cytopathology.

  2024cites this paper
• Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratory

  2024cites this paper
• The comparison of Real-Time PCR and mutation-specific immunohistochemistry in EGFR mutation analysis of non-small cell lung carcinomas

  2024cites this paper
• Validation and Implementation of a Somatic-Only Tumor Exome for Routine Clinical Application

  2024cites this paper
• Pulmonary Cytopathology: Current and Future Impact on Patient Care.

  2024cites this paper
• Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

  2024cites this paper
• Next-Generation Sequencing Trends among Adult Patients with Select Advanced Tumor Types: A Real-World Evidence Evaluation.

  2024cites this paper
• The Factors Associated With Mutant Epidermal Growth Factor Receptor Positivity in Patients With Lung Cancer: A Study From a Tertiary Care Center in Pakistan

  2024influential citation
• Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

  2024cites this paper
• Liquid biopsy for the management of NSCLC patients under osimertinib treatment

  2024cites this paper
• Two-Year Experience of a Center of Excellence for the Comprehensive Management of Non-Small Cell Lung Cancer at a Fourth-Level Hospital in Bogota, Colombia: Observational Case Series Study and Retrospective Analysis

  2024cites this paper
• Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.

  2024cites this paper
• Changes and Challenges in Molecular Diagnostics.

  2024cites this paper
• Epidermal growth factor receptor (EGFR) mutations in the serum of non–small cell lung cancer (NSCLC) patients as a marker to select patients for targeted therapy

  2024cites this paper
• Treatment of lung cancer by acupuncture combined with medicine based on pathophysiological mechanism: A review

  2024cites this paper
• Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology

  2023cites this paper
• Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC

  2023cites this paper
• Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients

  2023cites this paper
• Association of Reported Candidate Monogenic Genes With Lung Cancer Risk.

  2023cites this paper
• Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.

  2023cites this paper
• Advancement in Lipid-based Nanocomposites for Theranostic Applications in Lung Carcinoma Treatment

  2023cites this paper
• Prognostic and predictive biomarkers in non-small cell lung carcinoma.

  2023cites this paper
• A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology

  2023cites this paper
• Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.

  2023cites this paper
• Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.

  2023cites this paper
• Diversity and Disparities in Lung Cancer Outcomes Among Minorities

  2023cites this paper
• Guidelines for molecular testing in non-small cell lung cancer – recommendations from the Brazilian Society of Pathology

  2023cites this paper
• Immunotherapy and lung cytopathology: Overview and possibilities

  2023cites this paper
• Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

  2023cites this paper
• Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method

  2023cites this paper
• One procedure-one report: the Re-Imagine Cytopathology Task Force position paper on small tissue biopsy triage in anatomic pathology.

  2023cites this paper
• Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

  2023cites this paper
• Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis

  2023cites this paper
• Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report.

  2023cites this paper
• Real-World Impact of Robotic-Assisted Bronchoscopy on the Staging and Diagnosis of Lung Cancer: The Shape of Current and Potential Opportunities

  2023cites this paper
• Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non–Small Cell Lung Cancer and Colorectal Cancer

  2023cites this paper
• Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer

  2023cites this paper
• State of the Art of Pathologic and Molecular Testing.

  2023cites this paper
• EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing

  2023cites this paper
• Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities.

  2023cites this paper
• Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals

  2022cites this paper
• Implementation of an ISO15189 accredited next-generation sequencing service with the fully automated Ion Torrent Genexus: the experience of a clinical diagnostic laboratory

  2022cites this paper
• A Micro-Costing Framework for Circulating Tumor DNA testing In Dutch Clinical Practice.

  2022cites this paper
• The Performance of an Extended Next Generation Sequencing Panel Using Endobronchial Ultrasound-Guided Fine Needle Aspiration Samples in Non-Squamous Non-Small Cell Lung Cancer: A Pragmatic Study.

  2022cites this paper
• Highlights from the 7th Oncological Pathology Conference ‘Pathological Anatomy in the context of the National Cancer Law: An overview of the Latin American experience’, 15, 22 and 23 July 2022, Trujillo, Peru

  2022cites this paper
• Molecular/biomarker testing in lung cytology: A practical approach

  2022cites this paper
• Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study

  2022cites this paper
• Artificial Intelligence-Powered Prediction of ALK Gene Rearrangement in Patients With Non-Small-Cell Lung Cancer.

  2022cites this paper
• Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study

  2022cites this paper
• The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine

  2022cites this paper
• Exosomes from EGFR-Mutated Adenocarcinoma Induce a Hybrid EMT and MMP9-Dependant Tumor Invasion

  2022cites this paper